TY - JOUR
T1 - NTRK-rearranged mesenchymal tumours
T2 - diagnostic challenges, morphological patterns and proposed testing algorithm
AU - Wong, Daniel D.
AU - Vargas, Ana Cristina
AU - Bonar, Fiona
AU - Maclean, Fiona
AU - Kattampallil, Joseph
AU - Stewart, Colin
AU - Sulaiman, Ban
AU - Santos, Leonardo
AU - Gill, Anthony J.
PY - 2020/6
Y1 - 2020/6
N2 - Oncogenic fusions involving neurotrophic receptor tyrosine kinase (NTRK) genes are being increasingly identified in a range of mesenchymal tumours unrelated to infantile fibrosarcoma or cellular congenital mesoblastic nephroma, where the canonical ETV6-NTRK3 fusion was first described more than two decades ago. Recognition of these NTRK-rearranged tumours poses a diagnostic challenge to surgical pathologists due to their non-specific clinical and pathological features. However, their recognition is of heightened importance, particularly in locally advanced and metastatic sarcomas, due to the recent availability of selective and highly effective targeted therapy. Herein, we present an Australian multi-institutional series of six of these rare NTRK-rearranged mesenchymal neoplasms to share the local experience and diagnostic challenges as well as to highlight key morphological patterns and immunoprofiles that provide the most helpful clues in routine practice. We also propose a diagnostic algorithm for the detection of these fusions, drawing attention to the limitations of ancillary studies including immunohistochemistry against tropomyosin receptor kinase (TRK) protein, fluorescence in situ hybridisation (FISH) and next generation sequencing.
AB - Oncogenic fusions involving neurotrophic receptor tyrosine kinase (NTRK) genes are being increasingly identified in a range of mesenchymal tumours unrelated to infantile fibrosarcoma or cellular congenital mesoblastic nephroma, where the canonical ETV6-NTRK3 fusion was first described more than two decades ago. Recognition of these NTRK-rearranged tumours poses a diagnostic challenge to surgical pathologists due to their non-specific clinical and pathological features. However, their recognition is of heightened importance, particularly in locally advanced and metastatic sarcomas, due to the recent availability of selective and highly effective targeted therapy. Herein, we present an Australian multi-institutional series of six of these rare NTRK-rearranged mesenchymal neoplasms to share the local experience and diagnostic challenges as well as to highlight key morphological patterns and immunoprofiles that provide the most helpful clues in routine practice. We also propose a diagnostic algorithm for the detection of these fusions, drawing attention to the limitations of ancillary studies including immunohistochemistry against tropomyosin receptor kinase (TRK) protein, fluorescence in situ hybridisation (FISH) and next generation sequencing.
KW - entrectinib
KW - larotrectinib
KW - mesenchymal tumours
KW - NTRK
KW - pan-TRK
KW - sarcoma
KW - soft tissue tumours
KW - TRK
UR - http://www.scopus.com/inward/record.url?scp=85083016389&partnerID=8YFLogxK
U2 - 10.1016/j.pathol.2020.02.004
DO - 10.1016/j.pathol.2020.02.004
M3 - Article
C2 - 32278476
AN - SCOPUS:85083016389
SN - 0031-3025
VL - 52
SP - 401
EP - 409
JO - Pathology
JF - Pathology
IS - 4
ER -